FDA Approves FINTEPLA — UCB, Inc.

# FDA Approves UCB's Fintepla (Fenfluramine) for Rare Seizure Disorder UCB, Inc. received FDA approval for Fintepla (fenfluramine) oral formulation on June 25, 2020, marking a significant market opportunity in the rare pediatric epilepsy segment, particularly for Dravet syndrome and Lennox-Gastaut syndrome where the drug demonstrated meaningful clinical benefits. The approval positions UCB to capture a specialized but potentially lucrative niche within the anti-seizure medication market where treatment options are limited.